ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
FibroBiologics, Inc. Common Stock (FBLG) stock surged +9.50%, trading at $0.89 on NASDAQ, up from the previous close of $0.81. The stock opened at $0.84, fluctuating between $0.81 and $0.90 in the recent session.
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Employees | 10 |
Beta | -0.68 |
Sales or Revenue | N/A |
5Y Sales Change% | 0% |
Fiscal Year Ends | N/A |
Sector | Healthcare |
Industry | Biotechnology |
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep